The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): A prospective observational study

Tuesday, January 25th, 2022

This multicenter, prospective, observational cohort study evaluated the inflammatory phenotype and physiological characteristics of exacerbation events in 145 mepolizumab-treated patients aged 18–80 years with severe eosinophilic asthma. As part of the study, participants measured PEF twice daily using a Vitalograph Asma-1 peak flow meter.